Dionex ICS-5000 RFIC System Wins Bronze Star at GIT Innovations Award 2010
News Apr 30, 2010
Dionex Corporation announces that its new ICS-5000 Reagent-Free™ Ion Chromatography (RFIC™) system has been awarded the Bronze Star (3rd place) in the GIT Innovations Award 2010 in Category A, “Analytical Instruments and Software” by the GIT Labor-Fachzeitchrift magazine published, in Germany, for German speaking countries.
Introduced at Analytica 2010 in Munich, Germany, the ICS-5000 RFIC system made it through a rigorous selection process into the final round, was then voted for by conference attendees and GIT readers, and finally selected by a jury of independent university professors as one of the winners.
The ICS-5000 RFIC system combines all the award-winning features of other Dionex high-end products with capillary IC into one dual system. Using IC x IC technology in capillary and analytical modes, chemists can now achieve ultralow detection limits without the cost and operational challenges of a mass spectrometer.
Additionally, by using higher linear flow rates and pressure-optimized consumables, the ICS-5000 system has been optimized for Fast IC, which shortens run times to as low as 3–5 minutes, increasing laboratory throughput by up to four times. As capillary IC requires only 0.4 µL samples, the ICS-5000 system is an ideal platform for expanding into biological applications, such as metabolomics.
The ICS-5000 is fully supported by the popular Dionex Chromeleon® 6 and Chromeleon 7 Chromatography Data System software, providing extensive instrument control, data management, reporting, and compliance features.
BioAscent Establishes Integrated Drug Discovery Services OfferingNews
Dr Phil Jones to join as new CSO to lead company’s extended capabilities in medicinal chemistry and in vitro biosciences.READ MORE
Lab Innovations returns to the NEC, Bimingham , UKNews
Save the date for the UK’s only lab-dedicated exhibition showcase!READ MORE
A Breath Test for Early Diagnosis of Oesophageal and Gastric CancerNews
In a multi-centre clinical trial of 335 patients, a new breath test can identify oesophageal and gastric cancer from benign diseases with 85 per cent accuracy. Unlike other methods, the test is non-invasive.READ MORE
Comments | 0 ADD COMMENT
International Conference on Biobetters and Regulatory Affairs
Jun 27 - Jun 28, 2018